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Abstract
Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) is an autosomal
dominant neurodegenerative disorder, which has three cardinal features: behavioral and
personality changes, cognitive impairment, and motor symptoms. FTDP-17 was defined during the
International Consensus Conference in Ann Arbor, Michigan, in 1996. The prevalence and
incidence remain unknown but FTDP-17 is an extremely rare condition. It is caused by mutations
in the tau gene, which encodes a microtubule-binding protein. Over 100 families with 38 different
mutations in the tau gene have been identified worldwide. The phenotype of FTDP-17 varies not
only between families carrying different mutations but also between and within families carrying the
same mutations. The pathogenetic mechanisms underlying the disorder are thought to be related
to the altered proportion of tau isoforms or to the ability of tau to bind microtubules and to
promote microtubule assembly. Definitive diagnosis of FTDP-17 requires a combination of
characteristic clinical and pathological features and molecular genetic analysis. Genetic counseling
should be offered to affected and at-risk individuals; for most subtypes, penetrance is incomplete.
Currently, treatment for FTDP-17 is only symptomatic and supportive. The prognosis and rate of
the disease's progression vary considerably among individual patients and genetic kindreds, ranging
from life expectancies of several months to several years, and, in exceptional cases, as long as two
decades.
Disease name and synonyms
Frontotemporal dementia and parkinsonism linked to
chromosome 17 (FTDP-17).
Definition/diagnostic criteria
The term frontotemporal dementia and parkinsonism
linked to chromosome 17 was defined during the Interna-
tional Consensus Conference in Ann Arbor, Michigan, in
1996 [1]. At the time, affected individuals with frontotem-
poral dementia and parkinsonism linked to the wld locus
on chromosome 17 had been identified within 13 fami-
lies. This syndrome is a familial disorder with autosomal
dominant inheritance. The three major clinical features
include behavioral disturbances, cognitive impairment,
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and parkinsonism. There are no strict diagnostic criteria
for FTDP-17. Nevertheless, FTDP-17 should be considered
in the differential diagnosis in the presence of one or more
of the following [2]:
• Age of onset of neurological symptoms between the
third and fifth decades;
• Progressive neuropsychiatric syndrome including per-
sonality and behavioral abnormalities and/or frontotem-
poral dementia;
• Parkinsonism-plus syndrome (bradykinesia, rigidity,
postural instability, paucity of resting tremor, and poor or
no response to dopaminergic therapy) frequently associ-
ated with falls and supranuclear gaze palsy and less com-
monly associated with apraxia, dystonia, and
lateralization;
• Progressive speech difficulties from the onset of the ill-
ness;
• Seizure disorder poorly controlled by standard anticon-
vulsant therapy;
• Positive family history suggestive of autosomal domi-
nant inheritance of a neurodegenerative disorder, even if
there has been variability in clinical presentations.
Epidemiology
FTDP-17 is an extremely rare condition. Its prevalence and
incidence remain unknown. Over 100 families with
FTDP-17 have been reported to date in numerous coun-
tries (USA, Great Britain, Japan, Netherlands, France, Can-
ada, Australia, Italy, Germany, Israel, Ireland, Spain and
Sweden). Some of these families share a common founder
[3]. We estimate that there have been about 50–600
patients described, with fewer than 70 individuals still liv-
ing. Molecular genetic studies have identified 38 unique
mutations in these families (Figure 1). The most common
mutations, accounting for approximately 60% of known
cases, are P301L, N279K and a splice site mutation (exon
10 +16) [4].
Etiology
Mutations in the tau gene account for the vast majority of
FTDP-17 cases. Tau is a microtubule-binding protein
abundant in neurons and glia. In neurons, it is predomi-
nantly expressed in axons. Tau binds to and stabilizes
microtubules and promotes microtubule assembly. The
majority of the currently known mutations in coding
region occur within the microtubule-binding region of tau
gene. Most known mutations in non-coding regions affect
the splicing of exon 10 [4]. The pathogenetic mechanisms
in FTDP-17 are thought to be related to the altered pro-
portion of tau isoforms or to the ability of tau to bind
microtubules and to promote microtubule assembly.
Schematic representation of the exons and introns of the tau gene localized on chromosome 17 Figure 1
Schematic representation of the exons and introns of the tau gene localized on chromosome 17. The 38 mutations identified 
so far are presented.
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Mutations in tau gene associated with FTDP-17 fall into
two broad mechanistic groups. One group contains cod-
ing mutations (missense and two deletions) that, in
recombinant protein studies and in transfected cell assays,
have been shown to disrupt the binding of tau to micro-
tubules. In addition, the majority of these mutations have
also been shown to accelerate the aggregation of recom-
binant tau in the presence of polyanions. Thus, overall,
these mutations are predicted both to increase the propor-
tion of tau that is unbound to microtubules and available
for aggregation and also to increase directly the tendency
of the unbound tau to form filaments. The second group
of tau mutations appears to cause disease by disrupting
the alternative splicing of exon 10 and hence the ratio of
4R: 3R tau. These mutations comprise a mixture of coding
changes, within exon 10 (N279K, delK280, L284L,
N296N/H, delN296, P301L/S, G303V, and S305S/N) and
also intronic mutations close to the 5' splice site of exon
10 (at positions +3, +11, +12, +13, +14, +16, +19, and
+29). All but three of these mutations have been demon-
strated to increase the splicing-in of exon 10 and hence
the proportion of 4R tau. The exceptions are delK280,
+19, and, +29 mutations that show increased 3R: 4R ratio
as compared with normal condition [5]. The +29 muta-
tion has been detected in both affected individuals with
the FTD phenotype and normal controls [6-8]. Therefore,
it is still unclear whether this splicing mutation contrib-
utes to disease development.
Families with FTD linked to chromosome 17q21 without 
tau mutations
Six FTDP-17 kindreds have been identified in which nei-
ther a tau mutation nor tau pathology has been detected,
despite genetic linkage to the same region of chromosome
17q21 that contains the tau  gene [7-12]. Their clinical
phenotype is indistinguishable from that of cases with
known tau mutations. The specific mutations and their
clinical presentations are summarized in Table 1. Studies
of this group of individuals provide valuable information
for elucidating the etiology of FTDP-17, as it introduces
the possibility that further mutations in the introns or reg-
ulatory regions of tau, or other causative genes near the tau
locus may yet be discovered. For example, mutations in
the intronic sequence adjacent to the stem loop structure
in exon 10 have been identified that alter tau splicing to
increase soluble 3R tau, leading to increased tau proteoly-
sis and neuronal apoptosis without deposition of insolu-
ble tau aggregates [13].
Extensive ubiquitin-positive, tau-negative, cytoplasmic
and intranuclear neuronal inclusions have been observed
in layer II of the cerebral cortex and in the dentate gyrus of
Table 1: Families with FTD linked to chromosome 17q21 without tau mutations.
Author Froelich et al. [7] Rosso et al. [8] Lendon et al. [9]* Rademakers et al. [10] Kertesz et al. [11] Bird et al. [12]†
Karolinska Dutch III HDDD2 1083 Kertesz Seattle B
Pedigree
Origin Sweden Germany USA Netherlands Canada USA
No. of FA/G/AI 20/4/11 NA/4/32 >10,000/8/24 73/4/16 30/4/10 52/4/18
Mean ± SD age at 
onset, y
51 ± 3.6 61.2 ± 8.8 60.4 ± 0.5 64.9 ± 8.9 63.4 ± 12.5 54.7 ± 7.5
Mean ± SD disease 
duration, y
2.9 ± 0.8 8.6 ± 2.9 6.9 ± 2.2 6.6 ± 2.6 4.0 ± 2.7 10.1 ± 5.2
Clinical 
characteristics
Initial sign D D/PC D D/PC PC PC (PS)
Dementia + + + + + +
Other features Apraxia, dysphagia LD LD, EP, hemiparesis LD LD, dysphagia Myoclonus
Predominant clinical 
phenotype
FTD FTD FTD (HDD) FTD FTD (Pick 
complex)
FTD
Pathologic findings Severe frontal lobe 
degeneration with 
spongy changes and 
gliosis
Severe frontal lobe 
degeneration with 
neuronal loss and 
gliosis Neuronal loss 
in the hippo-campus
Severe frontal lobe 
degeneration with 
neuronal loss and 
gliosis Neuronal loss 
in the hippocampus
Frontotemporal 
degeneration with 
neuronal loss and 
gliosis
Frontotemporal 
lobe degeneration
Tau-positive NFT in 
the neocortex and 
limbic system
Ubiquitin-positive 
neuronal intranuclear 
inclusions
+ + NR + + NR
Max lod score for 
chromosome 17q21
2.68 3.46 3.68 5.51 1.68 1.11
+, present; AI, affected individual; D, dementia; EP, extrapyramidal signs; FA, family member; FTD, frontotemporal dementia; G, generation; HDD, 
hereditary dysphasic dementia; LD, language difficulties; NA, not available; NFT, neurofibrillary tangles; NR, not reported; PC, personality change; PS, 
psychiatric symptom.
*Data are from individuals with some form of dementia in recent generations of the familyOrphanet Journal of Rare Diseases 2006, 1:30 http://www.OJRD.com/content/1/1/30
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Table 2: Phenotypes of specific tau gene mutations seen in FTDP-17 patients.
Exon
Clinical feature 1 9 11 12 13 10 Intron 10
Average age at onset, y
≤30 S352L P301S
G335V
31–40 L266V S320F G389R delN296
S305N
G303V
41–50 G272V K317M E342V N279K +3 +11 +14
K257T P301L +16
>50 R5H I260V L315R V337M R406W del280K +12 +13 +19
R5L Q336R T427M L284L +29
K369I N296H
S305S
N296N
Average duration, y
≤5 R5H L266V L315R S352L G389R del280K +29
R5L K257T delN296
N296H
S305N
G303V
6–10 G272V I260V K317M E342V Q336R T427M N279K
P301L
+11 +12
K369I S305S
G335V N296N
L284L
P301S
11–15 S320F V337M +3 +14 +16
>15 R406W
First sign
Parkinsonism R5L K317M N279K +3 +11
P301L
delN296
S305S
N296N
G303V
Dementia R5H K257T S320F Q336R R406W L284L +3 +12 +29
L315R delN296
Personality change G272V L315R V337M T427M P301L +12 +14 +16
I260V E342V N296H +19 +29
K369I S305S
G335V S305N
Parkinsonism
Early-prominent K317M N279K +11
delN296
S305S
N296N
G303V
Late-prominent P301S +3 +12 +14
N296H +16 +29
Rare-minimal R5L G272V S352L P301L
S305N
Dementia
Early-prominent L266V S320F Q336R R406W delN296 +12 +29
K257T L315R G335V T427M S305S
I260V
Late-prominent G272V V337M del280K +3 +11 +13
K369I L284L
P301L
P301S
S305NOrphanet Journal of Rare Diseases 2006, 1:30 http://www.OJRD.com/content/1/1/30
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the hippocampus in three of the kindreds lacking a tau
mutation [14,15]. The intranuclear inclusions are unlikely
to result from a trinucleotide repeat expansion mutation
in that they failed to stain when exposed to an antibody
that recognizes proteins with polyglutamine tracts [7].
Descriptions of similar intranuclear inclusions in patients
with FTD and motor neuron disease [14,15] suggest that
they may turn out to be specific for chromosome 17-
linked FTD without tau mutations.
Clinical description
Symptoms and signs
The onset of FTDP-17 is usually insidious. Affected indi-
viduals who have reached the fully developed stage of the
disease present with a constellation of signs including at
least two of the three cardinal features of FTDP-17.
• Behavioral and personality disturbances;
• Cognitive deficits;
• Motor dysfunction (typically signs of parkinsonism-plus
syndrome).
Clinical features of FTDP-17 vary considerably among
affected individuals, regardless of whether they inherit the
same or different mutations. Even members within a fam-
ily, for example, can vary in their clinical presentation.
The specific mutations and their characteristic clinical
presentations are summarized in Table 2.
The behavioral and personality abnormalities can include
disinhibition, apathy, defective judgment, compulsive
behavior, hyper-religiosity, neglect of personal hygiene,
alcoholism, illicit drug addiction, verbal and physical
aggressiveness, family abuse, and other manifestations.
While cognitive disturbances occur, memory, orientation,
and visuospatial function are relatively preserved during
Rare-minimal K317M N279K
G303V
Personality change
Early-prominent L266V L315R V337M R406W del280K +12 +14 +16
G272V K369I T427M L284L +19 +29
I260V G335V P301L
K257T P301S
S305S
S305N
Other clinical features
Language s G272V S320F Q336R G389R N279K +14 +16 +29
difficultie K257T L315R T427M L284L
I260V K317M N296H
P301L
S305S
N296N
G303V
Late mutism L315R V337M R406W N279K +16 +29
T427M del280K
N296H
P301S
S305N
Eye movement N279K +3
abnormalities N296H
P301S
delN296
S305S
N296N
G303V
Epilepsy S352L P301S
Myoclonus V337M N279K +11
S352L P301S
Pyramidal signs N279K +3 +12
P301S
N296N
G303V
S305S
Amyotrophy K317M P301L
N296N
+14
Table 2: Phenotypes of specific tau gene mutations seen in FTDP-17 patients. (Continued)Orphanet Journal of Rare Diseases 2006, 1:30 http://www.OJRD.com/content/1/1/30
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early stages of the disease. Progressive speech difficulties
with non-fluent aphasia and disorders of executive func-
tions can be seen initially. Subsequently, memory, orien-
tation, and visuospatial functions progressively
deteriorate, while echolalia, palilalia, verbal and vocal
perseverations develop. Finally, progressive dementia and
mutism occur. Motor signs are also prominent. Parkin-
sonism can be the first manifestation of the disease, and
in this regard it is important to note that some FTDP-17
patients were initially misdiagnosed as having Parkinson's
disease or sporadic progressive supranuclear palsy. In
some families, however, the parkinsonism occurs late in
the course of the illness or not at all. The parkinsonism in
FTDP-17 is characterized by rather symmetrical bradyki-
nesia, postural instability, rigidity affecting equally axial
and appendicular musculature, (usually) absence of rest-
ing tremor, and poor or no responsiveness to levodopa
therapy. Other motor disturbances seen in FTDP-17
include dystonia unrelated to medications, supranuclear
gaze palsy, upper and lower motor neuron dysfunction,
myoclonus, postural and action tremors, eyelid opening
and closing apraxia, dysphagia, and dysarthria.
Phenotype-genotype correlations
It is still very difficult to perform precise phenotype/geno-
type correlations in FTDP-17 since the clinical informa-
tion available for some families is not detailed enough in
or not accessible at all. Nevertheless, some patterns have
emerged. The families with FTDP-17 fall into two major
groups [16]:
• dementia predominant phenotype;
• parkinsonism-plus predominant phenotype.
The dementia predominant phenotype is more common
and is usually seen in families with mutations in exons 1,
9, 11, 12, 13 and in exon 10.
A) Head MRI (left panels) demonstrates cortical atrophy in frontal and temporal lobes Figure 2
A) Head MRI (left panels) demonstrates cortical atrophy in frontal and temporal lobes. Positron emission tomography (PET) 
with 2-deoxy-2-fluoro- [18F]-D-glucose (FDG) PET (right panels) demonstrates hypometabolism in the same cortical regions. 
Middle panels show co-registration of MRI and FDG PET studies. B) Thermoregulatory sweating tests in the same patient with 
PPND. Shaded areas represent sweating over the anterior body surface. Distal anhidrosis is seen.Orphanet Journal of Rare Diseases 2006, 1:30 http://www.OJRD.com/content/1/1/30
Page 7 of 9
(page number not for citation purposes)
The parkinsonism-plus predominant phenotype is usu-
ally seen in families with intronic and exonic mutations
affecting exon 10 and leading to the selective overproduc-
tion of 4R tau isoforms. These categorizations should be
viewed cautiously until more clinical and pathologic data
become available.
Diagnostic methods
Characteristic clinical and pathological features of FTDP-
17 coupled with a molecular genetic analysis of the tau
gene are essential steps for a diagnosis.
Imaging studies such as computerized tomography (CT)
and magnetic resonance imaging (MRI) can assist in
establishing a diagnosis, mainly by excluding other diag-
nostic possibilities such as the presence of a brain tumor,
abscess, multi-infarct state, or hydrocephalus.
Imaging studies
CT and MRI of the head usually demonstrate some dila-
tion of the ventricular system and frontal, temporal, and
parietal cortical atrophy (Figure 2A) [17-22]. MRI T2-
weighted images may show accumulation of paramag-
netic substances (iron) in mesencephalic nuclei [19]. In
some kindreds, asymmetrical cortical atrophy is present.
Functional imaging studies such as single photon emis-
sion computerized tomography (SPECT) and positron
emission tomography (PET) also demonstrate significant
abnormalities. PET with 2-deoxy-2-fluoro- [18F]-D-glu-
cose (FDG) usually shows reduced frontal-parietal-tem-
poral uptake patterns similar to those seen in sporadic
frontotemporal dementia (FTD). PET with [18F]-fluoro-L-
dopa (6FD) and [11C]-raclopride tracers reveals uptake
abnormalities distinct from those seen in PD, in which the
putamen is affected more than the caudate nucleus [23].
Laboratory findings
The routine serum, urine, cerebrospinal fluid and other
body fluid studies are usually negative. Electroencepha-
lography (EEG) findings are normal early in the disease
process and progress to diffuse slowing as the disease
advances, although slowing can sometimes be seen earlier
in the course of the FTDP-17 illness [24]. In sporadic FTD,
the slowing of background rhythms usually occurs late in
the course of the illness. In individuals with the P301S
mutation, EEG demonstrates sharp waves, spikes and epi-
leptiform discharges [25]. Nerve conduction studies are
normal. Electromyography may show neurogenic patterns
related to lower motor neuron dysfunction [26]. Evoked
potential studies are usually normal. Autonomic testing
may show sudomotor impairment but not orthostatic
hypotension (Figure 2B) [27]. There is very little informa-
tion available on sleep studies in FTDP-17 kindreds. In a
clinicopathological study of an affected patient with
G389R mutation, a relationship between the reduced
delta sleep and the decreased cortical and subcortical con-
nectivity was reported [28]. Neuropsychological evalua-
tion is of paramount significance in determining the
severity and extent of cognitive and behavioral dysfunc-
tion in this disorder.
Differential diagnosis
Clinically, FTDP-17 may mimic several neurodegenerative
diseases. The differential diagnosis of FTDP-17 includes
disorders with initial signs such as behavioral and person-
ality abnormalities, parkinsonism, lower motor neuron
dysfunction or cognitive impairments. In the absence of a
positive family history or molecular genetic data, FTDP-17
is most frequently confused with Pick's disease, sporadic
progressive supranuclear palsy (PSP) or corticobasal
degeneration (CBD). Other familial frontotemporal
dementias, parkinson-plus syndromes, dementia with
Lewy bodies (DLB), Parkinson's disease (PD), multiple
system atrophy (MSA) should be excluded. A neuropatho-
logic examination coupled with molecular genetic analy-
sis of the tau  gene are essential steps towards
distinguishing FTDP-17 from other neurodegenerative
diseases associated with tau deposition. The pathologic
analysis should include immunohistochemical studies
using multiple anti-tau antibodies.
Genetic counseling
Affected individuals should be counseled regarding the
estimated probability of passing the genetic bases for their
illness on to their offspring. As FTDP-17 is an autosomal
dominantly inherited condition, each offspring of an
affected individual will carry a 50% risk of inheriting the
abnormal gene. Some of these mutations can be detected
through genetic testing. The individual who inherits a
mutation will not necessarily develop the same clinical
syndrome as the parent, because penetrance may be
incomplete, neurologic manifestations vary greatly even
within families, or the individual might die from unre-
lated causes. In the case of the pallido-ponto-nigral degen-
eration (PPND) subtype of FTDP-17, however, penetrance
is complete and virtually all individuals who inherit the
mutation will become symptomatic during middle age.
At-risk individuals may sometimes choose to adopt rather
than bear their own children. When faced with the option
of genetic testing, some people prefer the greater certainty
that a genetic diagnosis may afford when planning life
decisions, while others find not knowing to be a lesser
emotional burden as well as a lesser risk of being denied
healthcare should their insurance carrier learn the test
result. In either case the patient's choice should be
respected.Orphanet Journal of Rare Diseases 2006, 1:30 http://www.OJRD.com/content/1/1/30
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Inquiring into the family history can also identify relatives
who may be at risk of having inherited the genetic basis
for FTDP-17 and who thus may be presymptomatic.
Clinical genetic testing of affected and presymptomatic
individuals is commercially available for some mutations.
However, there tends to be little interest among at-risk
family members to undergo clinical genetic testing [29].
Antenatal diagnosis
Once a genetic basis for a subtype of FTDP-17 is discov-
ered and testing for that gene becomes commercially
available, it becomes possible, in principle, to identify
that gene antenatally by sampling amniotic fluid or by
preimplantation genetic diagnosis. Genetic counseling
should accompany antenatal genetic diagnosis.
Management including treatment
Currently, a curative treatment for FTDP-17 does not exist,
and most patients respond poorly, if at all, to levodopa.
Palliative and symptomatic interventions are the mainstay
of treatment. Physical therapy can be helpful to preserve
some measure of mobility and independence in activities
of daily living and to reduce the risk of falling. Stool sof-
tening agents are recommended for constipation. Speech
therapy, swallowing assessment, and switching to a softer
diet may be helpful for dysphagia. Anticholinergics may
be helpful for sialorrhea or urinary frequency but carry the
risk of aggravating mental confusion. Clozapine or
quetiapine may be helpful for psychosis not explained by
systemic infection or responsive to medication with-
drawal. Antidepressant medications may be indicated for
concurrent depression. Bed-bound patients will require
frequent repositioning or air flow mattresses. Patients
should be encouraged to discuss their treatment prefer-
ences with their families and their physicians and to indi-
cate their choices by advance directives.
Prognosis
The prognosis varies considerably. Most patients with
FTDP-17 will experience several months to one or two
years of moderate impairment followed by an unremit-
ting downward course of physical and cognitive decline.
The rate of progression varies greatly among individual
patients and genetic kindreds, ranging from life expectan-
cies of several months to several years, and, in exceptional
cases, as long as two decades. In addition to the clinical
features described above, in the late stages of illness these
patients often develop secondary medical problems asso-
ciated with immobility including falling injuries and res-
piratory and urinary tract infections.
Unresolved questions
It is hoped that further research will identify the genetic
modifiers and environmental factors that influence the
variable penetrance and clinical expression of FTDP-17.
The development of transgenic mice may provide an
opportunity to test novel therapeutic agents in the near
future.
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